UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, $4 PT

In a report published Friday, Piper Jaffray & Co. initiated coverage on Cytokinetics (NASDAQ: CYTK ) with an Overweight rating and $4.00 price target. Piper Jaffray noted, “We are initiating on Cytokinetics with an Overweight rating and $4 price target. In our view, the company's platform for treating diseases by